ARTICLE | Clinical News
Nalbuphine ER: Phase II/III started
July 21, 2014 7:00 AM UTC
Trevi began a double-blind, placebo-controlled, international Phase II/III trial to evaluate 60 and 120 mg oral Nalbuphine ER twice daily for 6 weeks in 360 hemodialysis patients with moderate to seve...